Absci Corp
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical company developing antibody therapeutics with an AI-native drug discovery approach. Its Integrated Drug Creation platform combines generative AI models, including Origin-1, with laboratory validation to design and optimize antibodies against… From the company’s description.
Over the twelve months to Jun 30, 2026, Absci Corp reported revenue of $1.56M, down 62.3% from a year earlier, and a net loss of $121.08M. Operations used $108.08M in cash. In fiscal 2025, it reported revenue of $2.80M, down 38.2% from fiscal 2024, and a net loss of $115.18M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Absci Corp does
In the company’s own words
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical company developing antibody therapeutics with an AI-native drug discovery approach. Its Integrated Drug Creation platform combines generative AI models, including Origin-1, with laboratory validation to design and optimize antibodies against biological targets. Absci advances internally developed programs and collaborates with pharmaceutical, biotechnology and other partners on drug creation, with potential arrangements including research funding, milestones and royalties. Its pipeline includes ABS-201, a prolactin receptor antibody in clinical development for pattern hair loss and planned development for endometriosis; ABS-101, a clinical-stage inflammatory bowel disease candidate for which the company is seeking a partner; and preclinical oncology and immunology programs, including ABS-301 and ABS-501. As of December 31, 2025, Absci was advancing five wholly owned internal programs, alongside additional early-discovery efforts. The company reported that its combined wet-lab and dry-lab facilities total more than 77,000 square feet. Its website is www.absci.com.
Company details
- Sector
- Industrials
- Industry (SIC)
- Professional Services
- Headquarters
- VANCOUVER, WA
- Fiscal year end
- December
- CIK
- 1672688
- SIC
- 8731
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Absci Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Absci Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Absci Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Absci Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Absci Corp's last four quarterly filings that the numbers alone won't show?”